Back to Results
First PageMeta Content
Sunitinib / Genentech / Renal cell carcinoma / Schistocyte / Food and Drug Administration / Thrombocytopenia / Microangiopathic hemolytic anemia / Medicine / Pharmacology / Bevacizumab


July[removed]IMPORTANT DRUG WARNING SUBJECT: Microangiopathic Hemolytic Anemia (MAHA) in Patients treated with Avastin® (bevacizumab) and sunitinib malate Dear Healthcare Provider:
Add to Reading List

Document Date: 2014-03-31 07:24:12

Open Document

File Size: 51,73 KB

Share Result on Facebook

City

Rockville / /

Company

Pfizer Inc. / Development Chief Medical Officer Genentech Inc. / Genentech Inc. / /

Event

FDA Phase / /

IndustryTerm

Healthcare professionals / /

MedicalCondition

proteinuria / congestive heart failure / hypertension / headache / NSCLC / fatal / pulmonary hemorrhage / leukopenia / metastatic renal cell carcinoma / asthenia / abdominal pain / solid tumors / neutropenia / nausea / reversible posterior leukoencephalopathy syndrome / stomatitis / thrombocytopenia / ileus / hemoptysis / nephrotic syndrome / intra-abdominal abscess / severe hypertension / syncope / pain / vomiting / fatigue / deep vein thrombosis / diarrhea / infection / Microangiopathic Hemolytic Anemia / constipation / intra-abdominal thrombosis / anemia / dehydration / /

MedicalTreatment

elective surgery / chemotherapy / /

Organization

FDA / Avastin administration / /

Person

Hal Barron / /

/

Position

Vice President / Fisher / /

Product

Avastin / Sutent / Avastin® (bevacizumab) / /

ProvinceOrState

Maryland / /

Technology

chemotherapy / /

URL

www.accessdata.fda.gov/scripts/medwatch / /

SocialTag